Alzheimer’s blood test, Aducanumab approval issues, Medicare coverage of brain scans that diagnose dementia, Some at higher risk for Alzheimer’s
Decision-making on antipsychotic medication use in assisted living needs system-level perspective: study
By
Kimberly Bonvissuto
Jan 25, 2023
Decisions on administering as-needed antipsychotic medications in assisted living/ residential care communities are based on attitudes, underlying morality and perceived expertise, requiring a system-level...
Vascular risk factors only explain part of Alzheimer’s disease risk for Blacks, Hispanics
Jan 11, 2023
Barriers to healthcare access and other socioeconomic factors may increase vulnerability in racial/ethnic minorities.
FDA approves second drug for Alzheimer’s disease, despite safety concerns
Jan 06, 2023
The approval of lecanemab-irmb (Leqembi) comes after controversial approval in 2021 of aducanumab (Aduhelm), which met with criticism over concerns about that drug’s effectiveness, safety and pricing.
Natural environments may cut hospitalization for patients with neurodegenerative diseases
Dec 30, 2022
The normalized difference vegetation index was negatively associated with hospitalization for Alzheimer’s disease and related dementia as well as Parkinson’s disease.
Congressional report slams FDA, drugmaker over approval of Alzheimer’s drug Aduhelm
Dec 29, 2022
The controversy over aducanumab (Aduhelm) stretches back to its June 2021 approval by the US Food and Drug Administration.
Senior living celebrates ‘big wins’ in proposed $1.7 trillion omnibus package
By
Kimberly Bonvissuto
Dec 21, 2022
Senior living advocates are claiming “major victories” for the industry following the release of the proposed $1.7 trillion congressional year-end spending bill on Monday.
Alzheimer’s Association asks CMS to provide full coverage of FDA-approved dementia drugs
By
Kimberly Bonvissuto
Dec 21, 2022
Every day, more than 2,000 older adults living with mild dementia may transition to a more advanced stage of the disease and no longer be eligible for lecanemab and other antibodies targeting amyloid under...
PET changes similar for Alzheimer’s disease, Down syndrome
Dec 20, 2022
“This study shows that, although there are subtle differences, Alzheimer’s disease pathophysiology is similar among people with Down syndrome and people with autosomal dominant Alzheimer’s...
Memory care breakthrough, or yet another false alarm?
By
John O'Connor
Dec 01, 2022
This week’s Alzheimer’s revelation is a hopeful sign, but even under the best possible scenario, much work remains.